Johnson & Johnson (JNJ) 10-K2021 FY Annual report

Filed: 17 Feb 22, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: abeyance, Academy, administered, Amgen, appellate, assumption, Atopic, barred, Bay, Bayview, bellwether, benzene, Bexar, Bone, Broadhurst, building, CABENUVA, CAD, certified, Charlotte, CIO, citizen, clawback, commodity, concurrently, consensual, contest, contested, creation, Crop, decide, decided, defect, degeneration, deployment, disqualify, docket, dual, durability, emotional, encompassing, equal, EUA, expatriate, extraordinary, Facilitation, factual, FCA, FCR, Fellow, Flex, Fontan, Francisco, fueled, Grail, HAFYERA, Hait, Harvard, Hawaii, house, HS, hybrid, hydration, ID, immunization, incorrect, Inflammation, insufficient, intermediate, Iowa, Israeli, jeopardized, Joaquin, Judiciary, Lauderdale, Leiden, LER, light, LTL, macular, Mammen, Mathai, mechanism, Medicine, MedTech, Merck, Michigan, mid, Minnesota, mission, misuse, MSA, Multidistrict, Nassau, nationwide, Nebraska, nonrecognized, Oakland, Occidental, older, opposition, opt, opted, ORSL, Ottava, oversaw, PAD, panel, Passaic, permission, PI, pJIA, Ponesimod, PONVORY, preemption, protocol, psychiatric, RAM, Rasmussen, recession, reconsideration, reexamination, Refractory, Relapse, Relapsed, Relapsing, Renal, repayment, requisite, resume, Revascularization, River, rolled, RYBREVANT, satisfaction, SC, seamlessly, secondary, Sedona, simultaneously, Sizer, small, solid, Sr, standalone, statute, storage, subdivision, Suffolk, Suggestion, sunscreen, Suppurativa, suture, Swanson, Tarrant, TCC, team, Teclistamab, temporarily, Theravance, thereof, timeline, Tolmar, training, Transformation, transformational, transmission, unchanged, undrawn, unequivocal, unspecified, Vanessa, Voice, warn, wholly, wide, William, withdrawn, wording, Writ, Wyoming

Removed: adding, agent, Alembic, Alex, AMO, Antibacterial, applicability, arbitration, awaiting, Belgium, binding, biodegradable, Biopharma, bortezomib, Brazil, BTG, Cadila, CBP, CECL, Cellex, Cipla, clarification, CRPC, encounter, ethanolate, existed, extension, feature, formally, gained, Gorsky, hMPV, implantable, informing, institution, interpretative, invalidating, Jabil, JULUCA, Latin, Lek, letter, Leukemia, LifeScan, Lymphocytic, lymphoma, macroglobulinemia, Managing, mantle, MedIdea, metastatic, methoxsalen, Minister, MONOCRYL, MSN, NIZORAL, OCD, overturn, PDS, pharmaq, phase, Poland, polymer, positively, posterior, presenting, preserve, pursuing, recognize, referendum, relationship, releasing, rituximab, RoC, RSV, safer, Shifting, Singapore, Sneed, SOFCAMTM, specialty, spent, stabilized, STRATAFIX, Submission, suffer, Sweden, Syncytial, Tibotec, tissuegen, UK, unclear, updated, UT, Uvadex, Uvar, VELCADE, VICRYL, Virco, Virology, Xts

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated JNJ transcripts

JNJ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

(1)the Company's Annual Report on Form 10-K for the fiscal year ended January 2, 2022 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




			/s/ Joaquin Duato
			Joaquin Duato
			Chief Executive Officer

Dated: February 17, 2022

This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.